In this setting, other gene expression signatures have demonstrated their role in predicting cetuximab activity in HNSCC, notably the Cl3-hypoxia group of six-cluster model proposed and validated by our group [4]. The gene discussed is ADGRL3; the disease is head and neck squamous cell carcinoma.